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OBJECTIVES In the present study, we investigated the effects of statins on serum levels of soluble CD40
ligand (sCD40L) in patients with familial hypercholesterolemia (FH).
BACKGROUND Atherosclerotic disease seems to involve inflammatory and immunologic mechanisms, and
sCD40L has recently been identified as one of the key players in the atherosclerotic process.
HMG-Co A reductase inhibitors, statins, have been recognized as immunomodulators and
reduce cardiovascular events and mortality, but the effects of statins on sCD40L has not been
clarified.
METHODS In a randomized, double-blind, clinical trial, as part of the Atorvastatin versus Simvastatin on
Atherosclerosis Progression (ASAP) trial, 110 patients with FH were given atorvastatin 80
mg/daily (n  57) or simvastatin 40 mg/daily (n  53) for two years.
RESULTS Our main findings were: 1) at baseline patients with FH had significantly higher (approxi-
mately 27-fold) serum levels of sCD40L than healthy controls; 2) statin therapy markedly
decreased serum levels of sCD40L (approximately 40% reduction); 3) this decrease in
sCD40L was found during both “aggressive” (i.e., atorvastatin) and “conventional” (i.e.,
simvastatin) statin therapy and was not correlated with the degree of reduction in cholesterol
levels.
CONCLUSIONS Our findings may suggest enhanced CD40L-CD40 interaction in FH and that this
inflammatory response may be downregulated by statins. (J Am Coll Cardiol 2003;41:
275–9) © 2003 by the American College of Cardiology Foundation
Inflammation and immunological processes are considered
to have essential roles for the initiation and progression of
atherosclerosis (1). Thus, activated T cells, monocytes, and
granulocytes have been reported in patients with cardiovas-
cular disease (CVD) with particular enhanced activation in
cells isolated from coronary sinus (2,3). Moreover, infiltra-
tion of blood-derived macrophages and T cells into the
vessel wall seems to be an important feature of the active
stages of atherosclerosis. However, the sequence of immu-
nomodulatory steps has not been identified, and it is not
clear which molecule(s) play a key role early in the devel-
opment of atherosclerosis.
Familial hypercholesterolemia (FH) is a lipid disorder
that predisposes to premature CVD. Clinical sequels of
CVD are preceded by silent changes with deposition of
oxidized low-density lipoprotein (LDL) in the vessel wall.
Changes in the arterial wall of the carotid intima and media,
measured as carotid intima media thickness (IMT), can
predict coronary artery disease (4,5) and are directly associ-
ated with risk of myocardial infarction and stroke (6).
Overwhelming evidence from clinical studies has demon-
strated that reducing LDL cholesterol (LDL-C) level with
statins results in a lower risk of cardiovascular events (7–11).
Moreover, the ASAP study (12), comprising 325 patients
with FH, showed that aggressive LDL-C reduction by
atorvastatin was accompanied by regression of IMT,
whereas conventional LDL-C reduction with simvastatin
only retarded progression. However, while the reduction of
cardiovascular events by statin therapy is associated with a
marked reduction in LDL-C, recent studies have suggested
that statins may have several other biological effects beyond
that of lipid lowering, such as anti-inflammatory and
antioxidatory properties (13). It is, therefore, possible that
the beneficial effect of statins in atherosclerotic disease, at
least partly, is relayed through its immunomodulatory prop-
erties.
To further elucidate these issues, we measured serum
levels of soluble CD40 ligand (sCD40L), a ligand in the
tumor necrosis factor superfamily, in patients with FH
during “aggressive” (i.e., atorvastatin) and “conventional”
(i.e., simvastatin) statin therapy as a substudy in the ASAP
trial. Raised circulating levels of sCD40L have been re-
ported in angina patients with particularly high levels in
those with unstable disease (14 –16), and enhanced
CD40L-CD40 interaction seems to be involved in athero-
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genesis (1,17). However, the role of CD40L in early and
asymptomatic atherosclerotic disease is mostly unknown.
METHODS
Patient population and controls. The study design and
baseline characteristics of the patient population have been
described elsewhere (12). Briefly, 110 patients with FH,
participating in the ASAP trial, were included in a random-
ized, double-blind clinical trial. Patients were given 80 mg
atorvastatin (n 57) or 40 mg simvastatin (n 53) daily on
an intention-to-treat basis. We examined serum levels of
sCD40L at baseline and after one and two years on statin
treatment. There were no significant differences in demo-
graphic or lipid parameters between the full ASAP cohort
(n  325) and the patients in this substudy (data not
shown). Most of the patients with FH were asymtomatic
with no clinical evidence of CVD, but 31 had diagnosed
CVD based on the presence of one of the following:
previous myocardial infarction, angina pectoris, peripheral
artery disease, or previous transient ischemic attack. How-
ever, none of these patients had unstable angina, and
patients with myocardial infarction within three months
before the study were not included. For comparison, age-
and gender-matched healthy blood donors (n  20) were
used as controls. The characteristics of the study population
are given in Table 1. The Institutional Review Boards of
both centers in the Netherlands approved the protocol, and
written consent was obtained.
Blood sampling protocol. Serum was collected as previ-
ously described (18) using pyrogen-free tubes without ad-
ditives (BD Vacutainer Systems, Belliver Industrial Estate,
Plymouth, United Kingdom). Immediately after blood col-
lection, the tubes were immersed into melting ice and
allowed to clot for 1 h before centrifugation at 1,000 g for 10
min. Serum samples were stored at 80°C in multiple
aliquots until analysis. Samples were thawed only once.
Enzyme immunoassays (EIA). Serum levels of sCD40L
were determined by EIA (detection limit, 0.03 ng/ml;
Bender Medsystems, Vienna, Austria) according to the
manufacturer’s instructions (intra- and interassay coefficient
of variation10%). Analysis was performed in duplicates in
a blinded fashion. All samples from a given patient were
analyzed in the same microtiter plate to minimize run-to-
run variability.
Miscellaneous. Cholesterol and triglyceride concentra-
tions were determined with commercially available enzy-
matic methods (Boehringer Mannheim, FRG, no. 237574,
and Sera-PAK, Miles, Italy, no. 6639, respectively) (12). To
determine high-density lipoprotein cholesterol, the polyeth-
ylene glycol 6000 precipitation method was used (12).
Low-density lipoprotein cholesterol was calculated by the
Friedewald formula. Intima media thickness was deter-
mined in laboratories at the two University Medical Centers
participating in the ASAP trial (12). High-sensitivity
C-reactive protein (hsCRP) was analyzed at TNO Gaubius
Laboratory, Leiden, Netherlands (19).
Statistics. Differences between groups were compared by
the Mann-Whitney U test for unpaired data. For sCD40L,
repeated measures analysis of variance was performed a
priori. If the outcome was significant, Wilcoxon’s rank-sum
test for paired data was performed a posteriori.
Kolmogorov-Smirnov tests of normality with Liljefors sig-
nificance correction was used to test the distribution of the
measured parameter at baseline. Relations between variables
were tested using Spearman’s rank-correlation test. The
level of statistical significance was chosen as p  0.05
(two-sided). The values are given as mean  SEM.
RESULTS
Baseline levels of CD40L. As can be seen in Figure 1,
serum levels of sCD40L were significantly elevated in
hypercholesterolemic patients compared with healthy con-
trols. In fact, while sCD40L was nearly undetectable in
healthy controls, the mean level was 10 ng/ml in the
patients with FH (approximately 27-fold higher), with no
overlap between patients and controls. Patients with CVD
(n  31) did not have significantly higher sCD40L (10.7 
0.77 ng/ml) levels than those without CVD (n 79) (8.4
1.2 ng/ml). In fact, the patients with the six highest levels of
sCD40L did not have CVD.
Statin-induced changes of sCD40L. In the ASAP trial,
we have previously reported significant changes in lipid
parameters, hsCRP, and IMT during statin therapy, with
Abbreviations and Acronyms
CVD  cardiovascular disease
EIA  enzyme immunoassay
FH  familial hypercholesterolemia
hsCRP  high-sensitivity C-reactive protein
IMT  intima media thickness
LDL  low-density lipoprotein
LDL-C  LDL cholesterol
sCD40L  soluble CD40 ligand
Table 1. Clinical Characteristics of the Study Population
Atorvastatin Simvastatin Controls
n 57 53 20
Age, yrs 47  1 48  1 45  3
BMI, kg/m2 26  3 26  4 25  3
Gender, M/F 36/21 35/18 15/5
Smoking, % 69 81 73
CVD, % 24 32 0**
Total cholesterol, mmol/l 10.27  1.79 10.80  2.06 5.23  1.05**
HDL cholesterol, mmol/l 1.14  0.34 1.11  0.28 1.15  0.21
LDL cholesterol, mmol/l 8.30  1.74 8.92  2.01 3.76  0.06**
TG, mmol/l 1.92  0.92 1.86  1.03 1.12  0.10*
IMT, mm 0.96  0.25 0.92  0.20 —
Data are given as mean  SD unless otherwise specified. *p  0.05; **p  0.001
versus patients with familial hypercholesterolemia.
BMI  body mass index; CVD  cardiovascular disease; HDL  high-density
lipoprotein; IMT  intima media thickness; LDL  low-density lipoprotein; TG 
triglycerides.
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the most pronounced changes in the atorvastatin group
(12,19). As can be seen in Table 2, similar patterns were also
observed in this substudy, and, notably, these changes in
lipid parameters were accompanied by a marked reduction
in sCD40L levels after two years of therapy (approximately
40% reduction) (Fig. 2). There were no differences between
atorvastatin and simvastatin treatment after two years, but
after one year, the reduction was significantly greater in the
atorvastatin group. However, sCD40L levels were lower in
the simvastatin group at baseline, and because the reduction
in sCD40L was inversely correlated with baseline levels (r
0.75, p 0.001, and r0.68, p 0.001, after one and
two years of therapy, respectively), this may represent a bias
when comparing changes between the two treatment
groups. The change in sCD40L after two years was not
correlated with the change in IMT (r  0.06), LDL (r 
0.07) or hsCRP (r  0.01) in either of the two treatment
groups. The statin effects were similar in those with or
without CVD (data not shown).
DISCUSSION
In the present study, we show that patients with FH are
characterized by significantly raised serum levels of sCD40L
compared with carefully matched healthy controls. More-
over, we found that both “aggressive” (i.e., atorvastatin) and
“conventional” (i.e., simvastatin) statin therapy significantly
reduced serum levels of sCD40L with no difference between
the two treatment groups. Our findings may suggest en-
hanced CD40L-CD40 interaction in FH and that this
inflammatory response may be downregulated by statins.
We and others have previously demonstrated raised
serum levels of sCD40L in angina patients with particular
high levels in those with unstable disease (14,15), and the
present results suggest that such an increase is not restricted
to symptomatic atherosclerotic disease. In fact, markedly
raised serum levels of sCD40L (approximately 25-fold
higher) were also found in this study in patients with FH,
mostly without evidence of CVD. Recently, Garlics et al.
(20) showed a trend toward raised serum levels of sCD40L
in asymptomatic patients with moderate hypercholesterol-
emia, but few patients were studied. Moreover, it was
recently reported that, in healthy middle-aged women,
plasma level of sCD40L 3.71 ng/ml was associated with
significantly increased relative risk of developing future
cardiovascular events (21). However, based on leakage from
platelets, measurements of sCD40L should preferably be
performed in serum or platelet-free plasma, and the results
obtained from “ordinary plasma” may be unreliable (15).
In the present study, we found that a significant reduction
in IMT during statin therapy was accompanied by a marked
reduction in sCD40L. Although the degree of changes was
not statistically correlated, this finding may further support
a link between atherogenesis and CD40L. In fact, it has
become clear that the dyad CD40-CD40L plays a pivotal
role in the pathogenesis of atherosclerosis. CD40 is ex-
Figure 1. Serum levels of soluble CD40 ligand (sCD40L) in 110 patients
with familial hypercholesterolemia (FH) compared with 20 gender- and
age-matched healthy controls (CTR). Data are given as median and 25th
to 75th percentiles. *p  0.001 versus controls.
Table 2. Lipid Parameters and IMT in Patients With Familial Hypercholesterolemia Receiving 80 mg Atorvastatin (n  57)
or 40 mg Simvastatin (n  53) Daily for 2 Years
Atorvastatin Simvastatin
Differences
in ChangesBaseline 1 Year 2 Years Baseline 1 Year 2 Years
Total cholesterol (mmol/l) 10.27  1.79 5.73  1.11‡ 5.69  1.03‡ 10.80  2.06 7.11  1.04‡ 6.79  1.08‡ 0.05
HDL cholesterol (mmol/l) 1.14  0.34 1.24  0.41‡ 1.23  0.36‡ 1.11  0.28 1.25  0.32‡ 1.20  0.32‡ 0.647
LDL cholesterol (mmol/l) 8.30  1.74 3.94  1.02‡ 3.92  0.97‡ 8.92  2.01 5.26  1.06‡ 4.97  1.02‡ 0.05
Triglycerides (mmol/l) 1.92  0.92 1.31  0.76‡ 1.31  0.68‡ 1.86  1.03 1.42  0.72‡ 1.48  0.94‡ 0.05
IMT (mm) 0.96  0.25 0.90  0.22‡ 0.87  0.21‡ 0.92  0.20 0.92  0.20 0.98  0.22† 0.001
hsCRP 4.1  5.7 2.4  3.3‡ 2.1  2.3‡ 3.7  5.3 2.0  2.1* 2.1  2.2† 0.534
*p  0.05; †p  0.01; ‡p  0.001 versus baseline. Data are given as mean  SD.
HDL  high-density lipoprotein; hsCRP  high sensitivity C-reactive protein; IMT  intima media thickness; LDL  low-density lipoprotein.
Figure 2. Serum levels of soluble CD40 ligand (sCD40L) in 110 patients
with familial hypercholesterolemia receiving atorvastatin 80 mg (n 57) or
simvastatin 40 mg (n  53) daily for two years (yr). Data are given as
median and 25th to 75th percentiles. Open bar  atorvastatin; hatched
bar  simvastatin. *p  0.01; **p  0.001 versus baseline.
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pressed on a variety of cells (e.g., lymphocytes, macro-
phages, vascular smooth muscle cells, and endothelial cells)
and is present in almost all cell types in human atheroscle-
rotic lesions with enhanced expression in advanced, rupture-
prone, and ruptured plaques (22,23). Moreover, binding of
CD40L to its receptor on cell membranes (i.e., CD40)
induces a diversity of responses with relevance to athero-
genesis such as enhanced synthesis of inflammatory
cytokines, chemokines, and tissue factor, upregulation of
adhesion molecules as well as activation of matrix metallo-
proteinases (22–28). In fact, interruption of CD40L-CD40
interaction has been shown to impair atherogenesis in LDL
receptor-deficient mice consuming a high-cholesterol diet,
significantly reducing the size and lipid content of atheroscle-
rotic lesions (28). Moreover, studies using CD40L/low-density
lipoprotein receptor or CD40L/apolipoprotein E double-
deficient mutant mice confirmed the crucial role for CD40
signaling during the initiation and progression of atheroscle-
rotic lesions in two different mouse strains (22,29).
The immunomodulatory effects of statin therapy are
extensively investigated, and we report a marked downregu-
lation of serum levels of sCD40L during such therapy. The
decrease in sCD40L was found during both “aggressive”
(i.e., atorvastatin) and “conventional” (i.e., simvastatin)
statin therapy and was not correlated with the degree of
reduction in cholesterol levels. The cholesterol-independent
effects of statins appear to be well documented in vitro and
in a growing number of experimental models (13,30,31),
and the results in the present study suggest that downregu-
lation of sCD40L could be added to the nonlipid effects of
statins. Whatever the mechanisms, the ability of statins to
decrease sCD40L levels in serum in FH, combined with
their previously reported downregulatory effects on CD40
expression on monocytes in patients with moderate hyper-
cholesterolemia (20), suggests that statins could impair
CD40L-CD40 interaction in vivo. Thus, based on the
potential pivotal role of CD40L-CD40 in all stages of
atherogenesis, downregulation of this interaction could
clearly contribute to the beneficial effects of statins in
cardiovascular disease.
We report that asymptomatic FH patients are character-
ized by markedly raised serum levels of sCD40L and, even
more importantly, concentration of this inflammatory me-
diator significantly decreased during both “aggressive” and
“conventional” statin therapy. These findings suggest en-
hanced CD40L-CD40 interaction in familial hypercholes-
terolemia, and our results further support the notion that
the beneficial effects of statins in cardiovascular disease are
partly relayed through immunomodulatory pathways.
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